Elicio Therapeutics, Inc. - Common Stock (ELTX)

ELTX stock results show that Elicio Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.

Elicio Therapeutics announced promising preliminary data from the AMPLIFY-7P Phase 1a study of ELI-002 7P, showing extended median disease-free survival in patients with mKRAS-driven solid tumors.

Elicio Therapeutics stock is down on Friday after the company announced a proposed public offering for shares of ELTX this morning.

Pre-market stock movers are a hot topic on Friday and we're breaking down all of the latest news sending shares higher and lower!

Elicio Therapeutics Unveils Promising Phase 1a Data For ELI-002 7P In mKRAS Tumors

ELTX stock results show that Elicio Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.

Elicio Therapeutics (NASDAQ: ELTX) Makes Strides In Growing Cancer Vaccination Industry

--News Direct--

ELTX stock results show that Elicio Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.

The 2024 Benzinga Virtual Healthcare Summit brings together top healthcare professionals and companies to discuss industry trends, advancements in technology, and the future of healthcare. Don't miss out on this must-attend event!

--News Direct--

A clinical-stage biotechnology company has published promising preclinical data in Cancer Immunology Research, a journal of the American Association for Cancer Research (AACR).